

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/575,096
Filing Date	April 10, 2006
First Named Inventor	Harue NISHIYA
Art Unit	1635
Examiner Name	Jane J. ZARA
Attorney Docket Number	Q105188

U.S. PATENTS

Examiner Initials*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1					

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initials*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No	Foreign Document Number ³	Country Code ⁴	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
	1	1176195	EP	A1	2002-01-30	KYOWA HAKKO KOGYO CO., LTD.		
	2	03/055993	WO	A1	2003-07-10	KYOWA HAKKO KOGYO CO., LTD.		English Language Abstract
	3	1331266	EP	A1	2003-07-30	KYOWA HAKKO KOGYO CO., LTD.		

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T ⁵
	1	Supplementary European Search Report issued September 29, 2009, in EP 04773767.	
	2	Miyagashi, Makoto et al. "U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells" Nature Biotechnology, Nature Publishing Group, New York, NY, US, vol. 20, May 1, 2002. pp 497-499.	
	3	Shinkawa, Toyohide et al. "The Absence of Fucose but Not the presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity" Journal of Biological Chemistry, The American Society for Biochemistry and Molecular Biology, Inc., Vol. 278, No. 5, January 31, 2003. pp. 3466-3473.	
	4	Prati, Elisabetta G.P. "Antisense Strategies for Glycosylation Engineering of Chinese Hamster Ovary (CHO) Cells" Biotechnology and Bioengineering, Wiley & Sons, NJ, US, vol. 59, no. 4, August 20, 1998. pp. 445-450.	
	5	Kawasaki, Hiroaki et al. "Short hairpin type of dsRNAs that are controlled by tRNA val promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells" Nucleic Acids Research, Oxford University Press, Surrey, GB, vol. 31, no. 2, January 1, 2003. pp 700-707.	
	6	Mori, Katsuhiro et al. "Engineering Chinese Hamster Ovary Cells to Maximize Effector Function of Produced Antibodies Using FUT8 siRNA" Biotechnology and Bioengineering, Wiley & Sons, NJ, US, vol. 88, no. 7, December 30, 2004. pp. 901-908.	

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.